Procurement Summary
Country: Brazil
Summary: The Purpose of this Contract is the Acquisition of Medicines Intended to Comply with Court Decisions Made against the State of Rio Grande do Norte, in Compliance with Technical Specifications...
Deadline: 06 Jul 2026
Posting Date: 18 Jun 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 143544057
Document Ref. No.: 90085/2026
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
Object: Electronic Auction - The purpose of this contract is the acquisition of medicines intended to comply with judicial decisions made against the State of Rio Grande do Norte, observing the technical, quantitative and other specifications conditions contained in this Terms of Reference and in the Preliminary Technical Study ID 41291742. UASG code: 925550 Notice from: 06/18/2026 from 08:00 to 12:00 and from 13:00 to 17:00 Proposal Delivery: from 06/18/2026 at 08:00 AFLIBERCEPTE, CONCENTRATION 40 MG/ML, PHARMACEUTICAL FORM INJECTABLE SOLUTION, ADDITIONAL CHARACTERISTICS WITH APPLICATION SYSTEM Quantity: 3984 ATROPINE SULFATE, DOSAGE 5 MG/ML, USE OPHTHALMIC SOLUTION Quantity: 24 ATROPINE SULFATE, DOSAGE 10 MG/ML, USE OF OPHTHALMIC SOLUTION Quantity: 48 BETAXOLOL HYCLORHYDRATE, 0.5% CONCENTRATION, OPHTHALMIC SOLUTION PRESENTATION Quantity: 24 BIMATOPROST, DOSAGE 0.3 MG/ML, PRESENTATION OPHTHALMIC SOLUTION Quantity: 36 BIMATOPROST, COMPOSITION ASSOCIATED WITH TIMOLOL MALEATE, CONCENTRATION 0.3 MG + 5 MG/ML, PHARMACEUTICAL FORM OPHTHALMIC SOLUTION Quantity: 96 BRIMONIDINE TARTARATE, COMPOSITION ASSOCIATED WITH TIMOLOL MALEATE, CONCENTRATION 2 MG + 5 MG/ML, PHARMACEUTICAL FORM OPHTHALMIC SOLUTION Quantity: 24 CARBOMER, COMPOSITION ASSOCIATED WITH SORBITOL, CONCENTRATION 2 MG + 48.5 MG/G, PHARMACEUTICAL FORM OPHTHALMIC GEL Quantity: 144 CARMELLOSE SODIUM, CONCENTRATION 5 MG/ML, PHARMACEUTICAL FORM OPHTHALMIC SOLUTION Quantity: 240 CYCLOSPORINE, CONCENTRATION 0.5 MG/ML, PHARMACEUTICAL FORM OPHTHALMIC EMULSION Quantity: 3240 DEXAMETHASONE, CONCENTRATION 0.7 MG, PHARMACEUTICAL FORM OPHTHALMIC IMPLANT, ADDITIONAL CHARACTERISTICS WITH APPLICATION SYSTEM Quantity: 52 FARICIMAB, CONCENTRATION 120 MG/ML, PHARMACEUTICAL FORM INJECTABLE SOLUTION Quantity : 144 SODIUM HYALURONATE, MOTOR QUANTITY 0.15%, PHARMACEUTICAL FORM OPHTHALMIC SOLUTION Wh...
Documents
Tender Notice